Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy

References

• Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5):693–718.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2021 report. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed August 20, 2021.
   Google Scholar
• Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Global Initiative for Chronic Obstructive Lung Disease: the changes made. Cureus. 2019;11(6):e4985.
   PubMed Web of Science ®Google Scholar
• Singh D, Badadhel M, Brightling CE, et al. Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;202(5):660–671.
   PubMed Web of Science ®Google Scholar
• Sarwar MR, McDonald VM, Abramson MJ, Paul E, George J. Treatable traits in an English cohort: prevalence and predictors of future decline in lung function and quality of life in COPD. ERJ Open Res. 2021;7(2):00934–2020.
   PubMedGoogle Scholar
• Criner GJ, Bartolome RC, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023–1034.
   PubMed Web of Science ®Google Scholar
• MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):530–535.
   PubMedGoogle Scholar
• Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1045–1051.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.
   PubMed Web of Science ®Google Scholar
• Chen S, Small M, Lindner L, Xu X. Symptomatic burden of COPD for patients receiving dual or triple therapy. Int J Chron Obstruct Pulmon Dis. 2018;13:1365–1376.
   PubMed Web of Science ®Google Scholar
• Bathoorn E, Liesker JJW, Postma DS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009;4:101–109.
   PubMedGoogle Scholar
• Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037–2047.
   PubMed Web of Science ®Google Scholar
• Müllerová H, Hahn B, Simard EP, Mu G, Hatipoğlu U. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts. Int J Chron Obstruct Pulmon Dis. 2019;14:683–692.
   PubMed Web of Science ®Google Scholar
• McDonald VM, Osadnik CR, Gibson PG. Treatable traits in acute exacerbations of chronic airway diseases. Chron Respir Dis. 2019;16:1479973119867954.
   Web of Science ®Google Scholar
• Van‘t Hul AJ, Koolen EH, Antons JC, et al. Treatable traits qualifying for nonpharmacological interventions in COPD patients upon first referral to a pulmonologist: the COPD sTRAITosphere. ERJ Open Res. 2020;6(4):00438–2020.
   PubMedGoogle Scholar
• David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Sonnappa S, Postma DS, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J. 2017;50(1):1700761.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126.
   PubMed Web of Science ®Google Scholar
• Bafadhel A, Singh S, Jenkins C, et al. Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. Respir Res. 2020;21(1):17.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Chaudhry I, Pavord ID, et al. Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res. 2020;6(4):00188–2020.
   PubMedGoogle Scholar
• Voorham J, Corradi M, Papi A, et al. Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Res. 2019;5(3):00106–2019.
   PubMedGoogle Scholar
• Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–858.
   PubMed Web of Science ®Google Scholar
• Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D. Distribution, temporal stability and appropriateness of therapy of patients with COPD in the UK in relation to GOLD 2019. EClinicalMedicine. 2019;14:32–41.
   PubMedGoogle Scholar
• Alcazar-Navarrete B, Garcia-Rop F, Sanchesz G, et al. Burden of disease among exacerbating patients with COPD treated with triple therapy in Spain. Int J Chron Obstruct Pulmon Dis. 2020;16:2149–2161.
   Web of Science ®Google Scholar
• Kerkhof M, Tran TN, Soriano JJB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116–124.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Sonnappa S, Postma DS, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Resp J. 2017;50(1):1700761.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Voorham J, Dorinsky P, et al. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. 2020;75(9):744–753.
   PubMed Web of Science ®Google Scholar
• Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Resp J. 2018;51(4):1702536.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Monteagudoc M, Solntsevac I, Alcázar B. Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study. Arch Bronconeumol. 2021;57(1):13–20.
   PubMed Web of Science ®Google Scholar
• UK National Health Service. Quality and Outcomes Framework (QOF), enhanced services and core contract extraction specifications (business rules). Available from: http://www.hscic.gov.uk/qof. Accessed March 16, 2018.
   Google Scholar
• Clinical Practice Research Datalink. Available from: http://www.cprd.com/home. Accessed November 11, 2020.
   Google Scholar
• Boston Collaborative Drug Surveillance Program. The Clinical Practice Research Datalink. Available from: http://www.bu.edu/bcdsp/gprd. Accessed March 16, 2018.
   Google Scholar
• UK National Health Service. Hospital Episode Statistics (HES). Available from: http://content.digital.nhs.uk/hes. Accessed December 22, 2021.
   Google Scholar